[{"notes_id":"1_2280","category":"8","subcategory":"0","title":"Mefloquine","body":"Mefloquine (brand name Lariam) is used for both the prophylaxis and treatment of certain types of malaria. There has long been a concern about the neuropsychiatric side-effects of mefloquine. A recent review has however led to 'strengthened warnings' about the potential risks.<br \/><br \/>The following advice is therefore given:<br \/><ul><li>certain side-effects such nightmares or anxiety may be 'prodromal' of a more serious neuropsychiatric event<\/li><li>suicide and deliberate self harm have been reported in patients taking mefloquine<\/li><li>adverse reactions may continue for several months due to the long half-life or mefloquine<\/li><li>mefloquine should not be used in patients with a history of anxiety, depression schizophrenia or other psychiatric disorders<\/li><li>patients who experience neuropsychiatric sife-effects should stop mefloquine and seek medical advice<\/li><\/ul>","notes_hash":"e463fbe8c5c053105d73ce6ff7398672","knowledge_graph_node_id_link":0,"links":"<table style='width:100%'><tr><td>Medicines and Healthcare products Regulatory Agency<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_465\" data-linkid=\"465\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_465\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">2<\/span><button type=\"button\" style=\"\" id=\"link_dislike_465\" data-linkid=\"465\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_465\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">4<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"http:\/\/www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON336723\">November 2013 Drug Safety Update<\/a><\/td><\/tr><\/table>","media":"","concepts_for_notes":[],"category_name":"Pharmacology and therapeutics","subcategory_name":"","comment_count":0},"",[]]